ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 142 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q4 2021. The put-call ratio across all filers is 0.40 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $43,713 | -8.7% | 1,711 | +2.5% | 0.00% | – |
| Q2 2023 | $47,888 | +10.6% | 1,670 | -7.5% | 0.00% | – |
| Q1 2023 | $43,282 | +31.2% | 1,806 | -8.8% | 0.00% | – |
| Q4 2022 | $33,000 | 0.0% | 1,981 | -14.4% | 0.00% | – |
| Q3 2022 | $33,000 | -10.8% | 2,313 | -5.6% | 0.00% | – |
| Q2 2022 | $37,000 | -45.6% | 2,451 | -2.8% | 0.00% | – |
| Q1 2022 | $68,000 | -41.4% | 2,521 | -19.4% | 0.00% | – |
| Q4 2021 | $116,000 | -39.3% | 3,127 | -21.8% | 0.00% | – |
| Q3 2021 | $191,000 | +26.5% | 3,998 | -10.9% | 0.00% | – |
| Q2 2021 | $151,000 | -85.6% | 4,485 | -82.3% | 0.00% | -100.0% |
| Q1 2021 | $1,045,000 | +400.0% | 25,331 | +425.2% | 0.00% | +200.0% |
| Q4 2020 | $209,000 | +62.0% | 4,823 | +60.2% | 0.00% | – |
| Q3 2020 | $129,000 | +57.3% | 3,010 | +72.3% | 0.00% | – |
| Q2 2020 | $82,000 | +925.0% | 1,747 | +191.2% | 0.00% | – |
| Q1 2020 | $8,000 | – | 600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DFPG INVESTMENTS, LLC | 456,390 | $5,541,000 | 3.62% |
| DAFNA Capital Management LLC | 173,914 | $1,890,000 | 0.65% |
| One68 Global Capital, LLC | 19,861 | $216,000 | 0.47% |
| Diametric Capital, LP | 51,982 | $565,000 | 0.41% |
| ARK Investment Management | 1,383,756 | $15,041,000 | 0.38% |
| EAM Investors, LLC | 52,833 | $574,000 | 0.13% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 31,404 | $341,000 | 0.05% |
| Nikko Asset Management Americas, Inc. | 280,548 | $3,050,000 | 0.05% |
| MGO ONE SEVEN LLC | 14,900 | $161,000 | 0.04% |
| Qube Research & Technologies Ltd | 67,702 | $736,000 | 0.02% |